U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24ClFN4O3.ClH
Molecular Weight 471.353
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BX-471

SMILES

Cl.C[C@@H]1CN(CC2=CC=C(F)C=C2)CCN1C(=O)COC3=C(NC(N)=O)C=C(Cl)C=C3

InChI

InChIKey=FRUCNQBAWUHKLS-PFEQFJNWSA-N
InChI=1S/C21H24ClFN4O3.ClH/c1-14-11-26(12-15-2-5-17(23)6-3-15)8-9-27(14)20(28)13-30-19-7-4-16(22)10-18(19)25-21(24)29;/h2-7,10,14H,8-9,11-13H2,1H3,(H3,24,25,29);1H/t14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C21H24ClFN4O3
Molecular Weight 434.892
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11805137 | https://www.ncbi.nlm.nih.gov/pubmed/11054419 | https://clinicaltrials.gov/ct2/show/NCT00185341

BX 471 is an oral nonpeptide chemokine receptor1 (CCR1) antagonist that was under clinical development with Bayer Healthcare Pharmaceuticals (formerly Bayer Schering Pharma AG and Berlex) for the treatment of various inflammation-related disorders, including endometriosis. The CCR1 antagonist was also thought to have potential application in diagnostic imaging, particularly as an imaging biomarker for the diagnosis of Alzheimer's disease. Berlex initiated the development of the radiolabelled small molecule CCR1 antagonist, BX 471, for a specific diagnostic test for both early detection and for tracking disease progression following the discovery that the CCR1 protein was found in the brains of patients with Alzheimer's disease, and that increased levels of this protein were correlated with advancement of the disease. However, development of the agent for diagnostic imaging appears to have been discontinued. BX 471 was also in development for the treatment of autoimmune diseases, including multiple sclerosis and psoriasis; however, development in these indications, as well as multiple myeloma and endometriosis, also appears to have been discontinued. A phase II study of BX 471 in endometriosis had been completed.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16 μg × h/mL
4 mg/kg single, oral
dose: 4 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BX-471 FREE BASE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27 μg × h/mL
4 mg/kg single, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BX-471 FREE BASE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
4 mg/kg single, oral
dose: 4 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
BX-471 FREE BASE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3 h
4 mg/kg single, intravenous
dose: 4 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BX-471 FREE BASE plasma
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.
2000 Jun 23
Development of a multiple unit pellet formulation for a weakly basic drug.
2007 Mar
Patents

Patents

Sample Use Guides

To evaluate efficacy of BX 471 in the treatment of endometriosis associated pelvic pain BX 471 (600 mg) was administrated orally three times daily over 12 weeks.
Route of Administration: Oral
HEK 293 cells transfected with human or rat CCR1 were incubated with 125I-MIP-1a in the presence of increasing concentrations of BX471. Scatchard analysis of displacement binding studies with BX471 on rat CCR1 revealed that the affinity of the antagonist was 121 +/-60 nM ;100 times less effective for rat CCR1 than for human CCR1.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:15:42 GMT 2023
Edited
by admin
on Fri Dec 15 15:15:42 GMT 2023
Record UNII
L350B5LO1J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BX-471
Common Name English
UREA, N-(5-CHLORO-2-(2-((2R)-4-((4-FLUOROPHENYL)METHYL)-2-METHYL-1-PIPERAZINYL)-2-OXOETHOXY)PHENYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
BAY-865047
Code English
ZK811752
Code English
N-(5-CHLORO-2-(2-(4-(4-FLUOROBENZYL)-2(R)-METHYLPIPERAZIN-1-YL)-2-OXOETHOXY)PHENYL)UREA HYDROCHLORIDE
Systematic Name English
BAY-86-5047
Code English
ZK-811752
Common Name English
BAY86-5047
Code English
Bx 471 [WHO-DD]
Common Name English
Code System Code Type Description
EVMPD
SUB193709
Created by admin on Fri Dec 15 15:15:42 GMT 2023 , Edited by admin on Fri Dec 15 15:15:42 GMT 2023
PRIMARY
PUBCHEM
5311124
Created by admin on Fri Dec 15 15:15:42 GMT 2023 , Edited by admin on Fri Dec 15 15:15:42 GMT 2023
PRIMARY
EPA CompTox
DTXSID50183019
Created by admin on Fri Dec 15 15:15:42 GMT 2023 , Edited by admin on Fri Dec 15 15:15:42 GMT 2023
PRIMARY
SMS_ID
100000178106
Created by admin on Fri Dec 15 15:15:42 GMT 2023 , Edited by admin on Fri Dec 15 15:15:42 GMT 2023
PRIMARY
CAS
288262-96-4
Created by admin on Fri Dec 15 15:15:42 GMT 2023 , Edited by admin on Fri Dec 15 15:15:42 GMT 2023
PRIMARY
FDA UNII
L350B5LO1J
Created by admin on Fri Dec 15 15:15:42 GMT 2023 , Edited by admin on Fri Dec 15 15:15:42 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY